(3S,8R,9S,10R,13S,14S,17S)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,17-diyl dibenzoate | 42921-37-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (3S,8R,9S,10R,13S,14S,17S)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,17-diyl dibenzoate
• 英文别名: androstene-(5)-diyl-(3β.17β)-dibenzoate；Androsten-(5)-diyl-(3β.17β)-dibenzoat；3β,17β-Dibenzoyloxy-Δ⁵-androsten；[(3S,8R,9S,10R,13S,14S,17S)-17-benzoyloxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] benzoate
• CAS: 42921-37-9；71268-83-2
• 化学式: C₃₃H₃₈O₄
• 分子量: 498.662
• InChiKey: WXPROVOMHYNFTO-HFETUNNBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8
• 重原子数：
  37
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (3S,8R,9S,10R,13S,14S,17S)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,17-diyl dibenzoate 在 过氧乙酸 、 disodium hydrogenphosphate 作用下， 以 氯仿 为溶剂， 反应 6.0h， 以62%的产率得到5,6α-epoxy-5α-androstane-3β,17β-diol dibenzoate
  参考文献：
  名称：

  Kasal, Alexander; Podlaha, Jaroslav; Zajicek, Jaroslav, Collection of Czechoslovak Chemical Communications, 1991, vol. 56, # 5, p. 1070 - 1086

  摘要：

  DOI：
• 作为产物：
  描述：

  去氢表雄酮 在 4-二甲氨基吡啶 、 sodium tetrahydroborate 、 N,N'-二环己基碳二亚胺 、 potassium iodide 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 26.0h， 生成 (3S,8R,9S,10R,13S,14S,17S)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,17-diyl dibenzoate
  参考文献：
  名称：

  Synthesis and Antitumor Activity of Dehydroepiandrosterone Derivatives on Es-2, A549, and HepG2 Cells in vitro

  摘要：

  A series of dehydroepiandrosterone derivatives containing an acid ester was synthesized and evaluated for their antitumor activity on ES‐2, A549, and HepG2 cells by the MTT assay. Most compounds showed antitumor activity, while compounds 1c, 2i, and 2o exhibited more potential inhibitory effects compared with dehydroepiandrosterone on ES‐2 cells, A549 cells, and HepG2 cells, respectively.

  DOI：

  10.1111/j.1747-0285.2011.01311.x

文献信息

• Selective estrogen receptor modulator in combination with dehydroepiandrosterone (DHEA) or analogues
  申请人：ENDORECHERCHE INC.

  公开号：EP1623712A2

  公开（公告）日：2006-02-08

  Novel methods for the medical treatment and/or inhibition of the development of breast cancer, hypercholesterolemia, hyperlipidemia or atherosclerosis in susceptible warmblooded animals including humans involving administration of selective estrogen receptor modulator and an amount of a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-ene-3β,17β-diol, and compounds converted in vivo to one of the foregoing precursors. Further administration of bisphosphonates in combination with selective estrogen receptor modulators and/or sex steroid precursors is disclosed. Pharmaceutical compositions for delivery of active ingredients and kits useful to the invention are disclosed.

  用于治疗和/或抑制易感温血动物（包括人类）乳腺癌、高胆固醇血症、高脂血症或动脉粥样硬化发展的新方法，涉及给药选择性雌激素受体调节剂和一定量的性类固醇前体，这些前体选自脱氢表雄酮、硫酸脱氢表雄酮、雄-5-烯-3β,17β-二醇和在体内转化为上述前体之一的化合物组成的组。 此外，还公开了双膦酸盐与选择性雌激素受体调节剂和/或性类固醇前体的联合用药。本发明还公开了用于递送活性成分的药物组合物和试剂盒。
• Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
  申请人：Endorecherche, Inc.

  公开号：US20040157812A1

  公开（公告）日：2004-08-12

  Novel methods for the medical treatment and/or inhibition of the development of osteoporosis, breast cancer, hypercholesterolemia, hyperlipidemia or atherosclerosis in susceptible warm-blooded animals including humans involving administration of selective estrogen receptor modulator particularly compounds having the general structure: 1 and an amount of a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-ene-3&bgr;, 17&bgr;-diol and compounds converted in vivo to one of the foregoing presursor. Further administration of bisphosphonates in combination with selective estrogen receptor modulators and/or sex steroid precursor is disclosed for the medical treatment and/or inhibition of the development of osteoporosis. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.

  用于治疗和/或抑制易感温血动物（包括人类）骨质疏松症、乳腺癌、高胆固醇血症、高脂血症或动脉粥样硬化的发展的新方法，涉及给药选择性雌激素受体调节剂，特别是具有一般结构的化合物： 1 和一定量的选自脱氢表雄酮、硫酸脱氢表雄酮、雄-5-烯-3&bgr;，17&bgr;-二醇和在体内转化为上述前体之一的化合物组成的组的性类固醇前体。本研究还公开了双膦酸盐与选择性雌激素受体调节剂和/或性激素前体的联合用药，用于治疗和/或抑制骨质疏松症的发展。本发明还公开了用于输送活性成分的药物组合物和试剂盒。
• 158. The application of the method of molecular rotation differences to steroids. Part IV. Optical anomalies
  作者：D. H. R. Barton、J. D. Cox

  DOI：10.1039/jr9480000783

  日期：——
• Studies in the Synthesis of the Antirachitic Vitamins. II. Δ⁵-Androstenol-3 and its Partial Dehydrogenation with Benzoquinone^1,2
  作者：Nicholas A. Milas、Charles R. Milone

  DOI：10.1021/ja01209a005

  日期：1946.5
• SELECTIVE ESTROGEN RECEPTOR MODULATOR IN COMBINATION WITH DEHYDROEPIANDROSTERONE (DHEA) OR ANALOGUES
  申请人：Endorecherche Inc.

  公开号：EP1083905A2

  公开（公告）日：2001-03-21